New hope for kidney disease? experimental drug SLN12140 enters phase 2 trial
NCT ID NCT07553494
First seen May 08, 2026 · Last updated Jun 23, 2026 · Updated 9 times
Summary
This Phase 2 trial tests an experimental drug called SLN12140 in 48 adults with IgA nephropathy, a kidney disease that is not well controlled by standard treatments. Participants receive different doses of SLN12140 or a placebo by injection for 36 weeks, followed by an open-label period where everyone can get the drug. The main goal is to see if SLN12140 reduces protein in the urine, a sign of kidney damage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IGA NEPHROPATHY (IGAN) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing University 1st hospital
Beijing, Beijing Municipality, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SLN12140 (an experimental drug given by injection)
What this could lead to
If successful, this could lead to a new treatment option for people with IgA nephropathy whose disease is not well controlled by current standard therapies.
What could go wrong
This is an early Phase 2 trial with only 48 participants, so results may not apply to everyone. The drug may not work better than placebo, and side effects are still being studied.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.